A study recently published in the American Journal of Cardiology has explored the bleeding risk associated with oral anticoagulants (OACs) in patients with atrial fibrillation. Although direct oral anticoagulants (DOACs) have a favourable bleeding safety profile in...
The safety of direct oral anticoagulants in patients with atrial fibrillation and aged ≥ 85 years has been evaluated in a prospective Slovenian study. There were 2,260 patients with atrial fibrillation aged ≥ 65, who received dabigatran, rivaroxaban or apixaban...
Treatment and eradication of Helicobacter pylori (HP) infection is recommended due to its association with numerous gastrointestinal pathologies, it has been speculated that HP treatment could increase the risk of Clostridium difficile infection (CDI). An American...
Clinical pharmacy services are believed to reduce medication errors. Children are vulnerable to medication errors due to various factors. In a recent meta analysis, researchers undertook a qualitative and quantitative evaluation of the impact of clinical pharmacist...
Commonly prescribed direct oral anticoagulants for patients with non-valvular atrial fibrillation include apixaban and rivaroxaban, but there is a lack of compelling evidence to allow comparison of the two drugs. A recent retrospective cohort study has examined the...
